These results indicate that in prostate samples of patients with T2D, hyperglycemia could be a driver of the higher expression of those AKR1C members associated with oncogenic alterations, such as proliferation processes and HIF1α and NFκB pathways. This evidence concerns the gene NFKB1 and type 2 diabetes mellitus.